Literature DB >> 4028011

Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model.

J S Berek, A K Lichtenstein, R M Knox, T S Jung, T P Rose, J L Cantrell, J Zighelboim.   

Abstract

The antitumor effects of Corynebacterium parvum in a murine ovarian teratocarcinoma model depend upon a sequential activation of neutrophils and macrophages within the peritoneal cavity. We studied the sequential administration of biological response modifiers that independently activate each phase of the response. Tumor-challenged mice treated by i.p. injection of a pyridine-extracted fraction of cell-free Propionibacterium acnes (PA-PE, 1400 micrograms) demonstrated prolonged survival in less than 20% of the cases. An i.p. injection of a detoxified Salmonella endotoxin (DSE) preparation (150 micrograms) had no effect on tumor outgrowth. However, i.p. treatment with PA-PE (1400 micrograms), followed by 150 micrograms of DSE 1 day later, resulted in long-term survival (greater than 100 days) in 40 to 60% of mice. This antitumor effect was only evident when PA-PE was administered first (before DSE) and optimal when DSE was administered 24 h after PA-PE. The synergistic antitumor effect could be duplicated when tumor-challenged mice were first treated i.p. with peritoneal polymorphonuclear leukocytes, elicited by injection of PA-PE, and then treated with DSE 18 h later. These data indicate that appropriately timed injection of biological response modifiers with complementary effects can result in a synergistic prevention of tumor growth.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028011

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Bullatacin--in vivo and in vitro experience in an ovarian cancer model.

Authors:  C H Holschneider; M T Johnson; R M Knox; A Rezai; W J Ryan; F J Montz
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes.

Authors:  A Lichtenstein; J Berek
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.